ARBUTUS BIOPHARMA CORP — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a1a9c920-8875-4303-9e33-a3e93003011a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-33.5M | 2025-01-01 – 2025-12-31 | evidence 0001447028-26-000017 |
| FY 2024 | $-69.9M | 2024-01-01 – 2024-12-31 | evidence 0001447028-25-000083 |
| FY 2023 | $-72.8M | 2023-01-01 – 2023-12-31 | evidence 0001447028-24-000035 |
| FY 2022 | $-69.5M | 2022-01-01 – 2022-12-31 | evidence 0001447028-23-000018 |
| FY 2021 | $-76.2M | 2021-01-01 – 2021-12-31 | evidence 0001447028-22-000019 |
| FY 2020 | $-63.7M | 2020-01-01 – 2020-12-31 | evidence 0001447028-21-000021 |
| FY 2019 | $-153.7M | 2019-01-01 – 2019-12-31 | evidence 0001447028-20-000038 |
| FY 2018 | $-57.1M | 2018-01-01 – 2018-12-31 | evidence 0001447028-19-000006 |
| FY 2017 | $-84.4M | 2017-01-01 – 2017-12-31 | evidence 0001628280-18-003276 |
| FY 2016 | $-384.2M | 2016-01-01 – 2016-12-31 | evidence 0001628280-17-002760 |
| FY 2015 | $-62.7M | 2015-01-01 – 2015-12-31 | evidence 0001628280-18-003276 |
| FY 2014 | $-38.8M | 2014-01-01 – 2014-12-31 | evidence 0001171843-15-001398 |
| FY 2013 | $-14.1M | 2013-01-01 – 2013-12-31 | evidence 0001171843-15-001398 |
| FY 2012 | $29.6M | 2012-01-01 – 2012-12-31 | evidence 0001171843-15-001398 |
| FY 2011 | $-10.1M | 2011-01-01 – 2011-12-31 | evidence 0001171843-14-001132 |
| FY 2010 | — | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-134709 |
| FY 2009 | — | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-134709 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ARBUTUS BIOPHARMA CORP — all facts · Revenue · Operating Income